The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial

NCT03182634 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

1150

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Neratinib
DRUG: AZD5363
DRUG: Olaparib
DRUG: AZD6738

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

[object Object]